Ceribell vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ceribell (Nasdaq: CBLL) makes the only FDA-cleared AI point-of-care EEG for seizure detection in all patient ages; reported $89.1M revenue in 2025 (+36% YoY) with 2026 guidance of $111–$115M.
About
Ceribell is a commercial-stage medical technology company that has reimagined the electroencephalogram (EEG) for the acute care setting. Its flagship product is a rapid-application, disposable EEG system with an AI algorithm called Clarity that detects electrographic seizures in real time. The platform is FDA-cleared for use across all patient ages — from pre-term neonates through adults — making it the only point-of-care EEG with that breadth of clearance. In December 2025, Ceribell received additional FDA 510(k) clearance for its AI-powered delirium monitoring solution, the first and only FDA-cleared delirium screening and monitoring device.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.